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Abstract The expression pro¢les of eight cell lines derived
from T-cell malignancies were compared to CD4-positive T-cells
using cDNA microarray technology. Unsupervised hierarchical
clustering of 4364 genes demonstrated substantial heterogeneity
resulting in four distinct groups. While no genes were found to
be uniformly up- or down-regulated across all cell lines, we
observed 111 over-expressed genes (greater than two-fold) and
1118 down-regulated genes (greater than two-fold) in the lym-
phomas as a group when compared to CD4-positive T-cells.
These included genes involved in cytokine signaling, cell adhe-
sion, cytoskeletal elements, nuclear transcription factors, and
known oncogenes and tumor suppressor genes. Quantitative
£uorescent reverse transcription-polymerase chain reaction anal-
ysis demonstrated 70% concordance with the microarray results.
While freshly isolated malignant cells may di¡er in their individ-
ual expression patterns relative to established cell lines from the
same diagnoses, we feel that the variety of di¡erent lymphocytic
cell lines that we examined provides a representative picture of
the molecular pathogenesis of T-cell malignancies. 0 2002
Federation of European Biochemical Societies. Published by El-
sevier Science B.V. All rights reserved.
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1. Introduction
T-cell malignancies comprise approximately 10^20% of
non-Hodgkin’s lymphomas in the USA and Europe [1,2]
and can develop at di¡erent stages in the pathway of normal
T-cell di¡erentiation. Precursor lymphoblastic lymphomas are
derived from immature (thymus-based) lymphocytes, while
peripheral T-cell lymphomas arise from mature T-lympho-
cytes in peripheral nodal and extranodal sites [3,4]. The mech-
anisms involved in T-cell lymphomagenesis and progression
are not well de¢ned, in part due to the infrequent nature of
these neoplasms. In contrast to B-cell lymphomas, character-
istic chromosomal translocations are found in a small subset
of peripheral T-cell lymphomas. Chromosomal translocations
or inversions of the TCL1 locus at chromosome 14q21.1 are
seen in a subset of T-prolymphocytic leukemias [5], and the
t(2;5) translocation involving the NPM-ALK gene is seen in
anaplastic large cell lymphomas (ALCLs) [6,7]. The speci¢c
molecular abnormalities underlying many of the other classes
of T-cell lymphoma are currently unknown.
Complementary DNA (cDNA) microarrays are now widely
used to analyze global gene expression patterns [8^10]. This
technology permits the identi¢cation of pathologically rele-
vant gene expression patterns on a genomic scale, and also
allows a simultaneous comparison of the relative expression
levels for several thousand genes between di¡erent cell types
or tissue samples. DNA microarrays have been used to iden-
tify gene expression pro¢les associated with speci¢c patholog-
ical processes and malignancies [11^14]. Analysis of di¡eren-
tially expressed genes identi¢ed by this technology may
further our understanding of the possible role these genes
might play in the progression of various diseases and malig-
nancies. Additionally, the expression patterns of particular
genes may serve as molecular markers for the diagnosis of
speci¢c disease states.
In this study, we have compared expression patterns of
genes from eight cell lines derived from T-cell malignancies
to those of CD4-positive peripheral blood T-lymphocytes us-
ing cDNA derived from a ‘composite’ group of ¢ve lympho-
ma cell lines as a reference sample. Our results demonstrate
patterns of di¡erential gene expression distinct for each sam-
ple, which may be associated with characteristics speci¢c to
each category of malignancy. We found genes uniquely up-
regulated within each class of lymphoma, which may serve to
distinguish molecular changes related to the development of
each type of T-cell lymphoma. Additionally, we found a num-
ber of unknown genes (indicated by expressed sequence tags,
ESTs) exhibiting di¡erential expression in each of the various
lymphoma cell lines.
2. Materials and methods
2.1. Cell lines
Cell lines established from various T-cell malignancies were main-
tained in culture, in RPMI 1640 medium (Novatech, Inc., Grand
Island, NE, USA) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum and an antibiotic/antimycotic mixture (Gibco BRL,
Rockville, MD, USA). Each cell line was grown to con£uency, and
samples (consisting of approximately 107 cells) from each cell type
were used as ‘test sample’ sources for mRNA.
The Jurkat and CCRF-CEM lines are immature TCRKLþ T-lym-
phocytes, derived from acute lymphoblastic leukemias (ALLs) [15,16].
The Hut 78 and HH lines are derived from mature peripheral T-lym-
phocytes, established from two di¡erent stages of cutaneous T-cell
lymphoma (CTCL) [17,18]. Mac 2A was also derived from a CTCL,
but represents a cutaneous CD30-positive ALCL without the t(2;5)
translocation [19,20]. SUDHL-1 and Karpas 299 were derived from
ALCLs, which have a t(2;5)(p23;q35) translocation, producing an
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NPM-ALK fusion gene [21,22]. The SKW-3 line was established from
a mature peripheral T-cell chronic lymphocytic lymphoma (T-CLL)
[23,24].
Samples from each of the T-cell lymphoma cell lines and from
peripheral blood lymphocyte (PBL) T-cells (activated or control)
were compared to our reference sample, consisting of cDNAs derived
from total RNA from the Jurkat, SKW-3, NCEB (a mantle cell lym-
phoma-derived cell line), Raji (a mature B-cell t(8;14)-positive Bur-
kitt’s lymphoma line), and L-428 (a Hodgkin lymphoma) cell lines
[25^27].
2.2. Isolation and activation of PBL T-cells
PBLs from healthy donors were isolated by density-dependent cell
separation using Ficoll^Paque1 PLUS reagent (Amersham Pharma-
cia Biotech, Piscataway, NJ, USA). T-lymphocytes were phenotypi-
cally puri¢ed with anti-CD4 antibodies conjugated to magnetic beads
(Dynal, Inc., Lake Success, NY, USA).
2.3. mRNA preparation
TRIzol reagent (Gibco BRL) was used to extract total RNA ac-
cording to the manufacturer’s instructions. Residual DNA was re-
moved by treatment with RNase-free DNase, in the presence of the
ribonuclease inhibitor RNasin. The total RNA was phenol/chloro-
form-extracted, ethanol-precipitated and resuspended in DEPC-
treated RNase-free distilled water. Messenger RNA was obtained us-
ing the Qiagen Oligotex mRNA puri¢cation kit as described by the
manufacturer (Qiagen, Inc., Valencia, CA, USA).
2.4. Microarray analysis
Microarray analysis was performed in the core facility in the Hunts-
man Cancer Institute, University of Utah. This facility maintains a
sequence-veri¢ed 4364-clone collection supplied by Research Genetics
(Huntsville, AL, USA). The instrumentation used to print and scan
microarray slides has been developed by Molecular Dynamics (Sun-
nyvale, CA, USA) following principles previously described [8]. In
addition to these cDNA clones, we have customized our slides to
include a curated list of genes previously shown to be expressed in
subsets of lymphoid cells [28]. All hybridizations were performed in
quadruplicate. Di¡erential gene expression was investigated using a
simultaneous two-color hybridization scheme. Fluorescently labeled
cDNA was prepared from RNA by oligo dT-primed polymerization
using SuperScript II reverse transcriptase (Gibco BRL) in a 20 Wl
reaction. The pool of nucleotides in the labeling reaction consisted
of 50 WM dGTP, dATP, and dTTP, and 5 WM dCTP, in the presence
of 12.5 WM of the £uorescent nucleotides, Cy5 or Cy3 dCTP (Amer-
sham Pharmacia Biotech). The composite sample was labeled with
Cy3 dCTP (green £uorescence), while the test sample was labeled
with Cy5 dCTP (red £uorescence). After incubation at 42‡C for
2.5 h, the labeling reaction was stopped by the addition of 1.0 Wl of
5 M NaOH, with incubation at 37‡C for 10 min. The resulting alka-
line solution was partially neutralized with 2.5 Wl of 2 M Tris^HCl
(pH 7.5) and 1 Wl of 5 M HCl, and unincorporated nucleotides were
removed using the Qiagen polymerase chain reaction (PCR) clean-up
kit (Qiagen, Inc.). The two £uorescently labeled samples were mixed,
vacuum-concentrated, resuspended in hybridization bu¡er, and then
hybridized to the target genes on the microarray slides. Four replicate
samples for each cell line were added to separate slides and hybridi-
zation patterns were captured electronically using a two-color confo-
cal laser microscope. Analysis of array images was performed both by
visual inspection and electronic quantitation of the £uorescent inten-
sities of the individual spots. Visual inspection of microarray images
was performed with the assistance of the ImageQuant NT software
program (Molecular Dynamics, Sunnyvale, CA, USA). Electronic
spot quanti¢cation was achieved using the ArrayVision 4 software
program from Imaging Research (Ontario, Canada), which permits
assignment of numerical values indicative of the £uorescence inten-
sities of the individual spots. Once captured, the data were exported to
Microsoft Excel for further analysis.
2.5. Data analysis
Manipulation and interpretation of raw £uorescent signals into in-
terpretable data was performed using GeneSpring1 software (Silicon
Genetics, Redwood City, CA, USA). Data sets were loaded from
Excel and the Cy5 (red)/Cy3 (green) ratios were normalized for each
data set. Gene expression patterns were considered signi¢cant only
when maintained across at least three of four replicate hybridizations
[29]. The data were analyzed to identify those genes expressed at levels
two-fold above or two-fold below the composite sample values. Gene
lists were then compiled from the over- or under-expressed genes, and
clustering analysis was used to construct dendrograms for comparison
of the di¡erentially expressed genes in the eight lymphoma cell lines
and the CD4þ PBL T-cells.
2.6. Quantitative £uorescent reverse transcription (RT)-PCR analysis
First-strand cDNA synthesis was performed using 1.0 Wg of total
RNA and SuperScript II Reverse Transcriptase (Gibco BRL) accord-
ing to the manufacturer’s instructions. Fluorescent PCR analysis was
performed using the LightCycler1 (Roche Molecular Biochemicals,
Indianapolis, IN, USA) and SYBR Green I1 (Molecular Probes,
Eugene, OR, USA) as previously described [30,31]. Ampli¢cation re-
actions consisted of 40 cycles of denaturation at 94‡C (0 s), annealing
at 50‡C (10 s), and extension at 72‡C (15 s), using the primers listed in
Table 1. Fluorescent signals were obtained once in each cycle by
sequential-£uorescence monitoring of each sample tube at the end
of extension. Crossing thresholds (CTs) for each gene were obtained
using the second derivative maximum function of the Roche Light-
Cycler1 quantitation software. Ampli¢cations were repeated for each
pair of primers for the cDNA derived from each cell line and the
CT values were averaged. Normalization was accomplished by sub-
tracting the CTs obtained for the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) from the CTs of the genes of
interest, for each sample. A further normalization was then performed
for each primer set by subtracting the CTs derived from a composite
cDNA sample (comprised of 100 ng of cDNA from each of the com-
posite cell lines) from the CT values obtained for each test sample
for the same primer pair. The resulting normalized values were used
to determine the relative levels of up- or down-regulation for each
gene.
Table 1
Primers used for quantitative £uorescent RT-PCR analysis
Gene Primer Sequence
GAPDH Forward 5P-CGACCACTTTGTCAAGCTCA-3P
Reverse 5P-AGGGGAGATTCAGTGTGGTG-3P
Akt kinase 1 (AKT1) Forward 5P-GATGACAGATAGCTGGTG-3P
Reverse 5P-GCTGGACGATAGCTGGTG-3P
Human alpha 1 (ALPHA1) Forward 5P-GGTAACGATGGTGTCGAGGT-3P
Reverse 5P-GTTCCCACCCAGCATTACAG-3P
Endoglin 1 (ENG1) Forward 5P-CAACTGTGTGAGCCTGCTGT-3P
Reverse 5P-GACAGGTCAGGGCTGATGAT-3P
Myeloblastosis oncogene (v-MYB) Forward 5P-GTCGGAAACGTTGGTCTGTT-3P
Reverse 5P-TTCGTCCAGGCAGTAGCTTT-3P
Nuclear factor kappa B1 (NFKB1) Forward 5P-GCACGACAACATCTCATTGG-3P
Reverse 5P-TCCCAAGAGTCATCCAGGTC-3P
Prothymosin a28 (PTMA) Forward 5P-GCAAATCACCACCAAGGACT-3P
Reverse 5P-CTCCATCCTCTTCCTCACCA-3P
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3. Results
3.1. Microarray analysis
Gene expression pro¢les for eight cell lines derived from
T-cell malignancies and phenotypically puri¢ed CD4-positive
PB T-cells were compared, relative to the expression patterns
found within a reference sample (composite) consisting of a
mixture of ¢ve lymphoma cell lines. Use of a composite sam-
ple as a reference for microarray analysis permitted the iden-
ti¢cation of a large number of di¡erentially expressed genes
and also permitted comparisons of gene expression patterns
among the various cell lines. Since most of the T-lymphomas
we analyzed were derived from CD4-positive T-cells [32,33],
we used CD4-positive PB T-cells to provide a ‘baseline’ gene
expression pro¢le for normal T-cells for comparison.
Fig. 1a demonstrates the reproducibility of our microarray
analysis system. It shows a scatter plot of the composite refer-
ence sample cDNA labeled with Cy5 hybridized with the same
cDNA labeled with Cy3. Since the mRNA levels should be
virtually identical in the two cDNAs assayed, we would expect
little di¡erence in the expression levels between the two sam-
ples. Indeed, the majority of data points lie within one stan-
dard deviation of the (y= x) axis, with a very high correlation
coe⁄cient (r=0.994). Di¡erential expression of a gene was
considered to be present when the Cy5/Cy3 ratio was greater
than or equal to two standard deviations from the mean sig-
nal ratio of the entire array slide, and very few genes showed
£uorescent signal ratios outside of this limit, clearly establish-
ing the reliability of our analysis system.
As shown in Fig. 1, scatter plots of CD4þ T-cells (Fig. 1b),
Jurkat (Fig. 1c) and SUDHL-1 (Fig. 1d) hybridized to the
reference ‘composite’ cDNA show individual patterns of
gene expression.
Unsupervised hierarchical clustering (Fig. 2), using all 4364
genes, grouped samples according to the similarities of their
gene expression patterns. The CD4-positive PBL T-cells clus-
Fig. 1. Scatter plots of cDNA samples hybridized to the composite
reference sample. The cDNA samples from di¡erent cell types were
labeled with Cy5 and mixed with the composite samples labeled
with Cy3. Labeled samples were hybridized to slides containing
4364 di¡erent cDNA sequences and £uorescent signals were mea-
sured. Each data point represents a ratio of Cy5 (vertical axis) to
Cy3 (horizontal axis) £uorescent signals. Red data points represent
up-regulation and green data points represent down-regulation rela-
tive to the mean signal ratio of the entire array slide. The blue lines
represent two-fold di¡erences from the (y= x) axis. a: The compo-
site reference sample was hybridized vs. itself (the correlation coe⁄-
cient for the plot is r=0.994). b: CD4-positive T-cells were hybrid-
ized vs. the composite sample. c: The Jurkat lymphoma cell line
was hybridized vs. the composite sample. d: The SUDHL-1 lym-
phoma cell line was hybridized vs. the composite sample.
Fig. 2. Unsupervised hierarchical clustering of malignant T-cell lines
and CD4þ T-cells. Cell types were compared over the entire list of
genes used for the microarray without restriction. Adjacent samples
have the most similar expression pro¢les and the branching patterns
designate clustered groups with high relative degrees of similarity.
The top dendrogram represents a measure of the relatedness of the
hybridization signals across each of the samples and the dendro-
gram to the left is a measure of the relatedness in each sample, so
that samples exhibiting closely related expression pro¢les are located
in adjacent columns. Gene expression pro¢les for each individual
cell line or sample are designated on the right-hand side of the ¢g-
ure. The color bar indicates the expression levels for the genes
shown, with red indicating up-regulation, green representing down-
regulation, and gray signifying a lack of data for a speci¢c gene.
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Table 2
Genes up- or down-regulated in subgroups of T-lymphoma cell lines
Description GenBank Map Description GenBank Map
Up two-fold in ALCLs relative to CD4þ PBLs Down two-fold in ALCLs relative to CD4þ PBLs
glycogenina AA411678 3q24^q25.1 lymphocyte-speci¢c protein tyrosine
kinasea
AA469965 1p35^p34.3
protease inhibitor 2a (anti-elastase),
monocyte/neutrophil
R54664 !!6p25 myosin, light polypeptide 6 AA488346 12
interleukin 1 receptor, type I AA464525 2q12 pro¢lin 1 AA521431 17p13.3
interleukin 2 receptor, beta AA057156 22q13.1 villin 2 (ezrin) AA411440 6q25^q26
interleukin 1 receptor, type II H78484 2q12^q22 tumor necrosis factor receptor
superfamily, member 12
R34121 1p36.2
Homo sapiens protein tyrosine
phosphatase type IVA
R61674 moesin R22977 Xq11.2^q12
natural killer cell transcript 4 AA458965 16p13.3 ¢lamin A, alpha (actin-binding
protein-280)
AA478436 Xq28
neuronal cell adhesion molecule R25521 7q31.1^q31.2 transcription factor 7 (T-cell-speci¢c,
HMG-box)
AA480071 5q31.1
hemopoietic cell kinase AA149096 20q11^q12 human alpha 1 AF001540 11q13
integrin, beta 4 AA485668 17q11^qter human HLA-DR alpha-chain mRNA R47979
+9 ESTs +38 ESTs
Up two-fold in ALLs Down two-fold in ALLs
ovarian granulosa cell protein
(13 kDa)
R63543 X major histocompatibility complex,
class II, DQ beta 1a
AA442984 6p21.3
cold shock domain protein A AA465019 12p13.1 human HLA-DR alpha-chain mRNAa R47979
natural killer cell transcript 4 AA458965 16p13.3 caspase 8, apoptosis-related cysteine
protease
AA448468 2q33^q34
ubiquitin carrier protein E2-C AA430504 20 S-phase kinase-associated protein 2
(p45)
R22239 5p13
annexin A1 H63077 9q11^q22 vinculin AA486728 10q22.1^q23
major histocompatibility complex,
class II, Y box-binding I
AA599175 1p34 interleukin 18 (interferon-gamma-
inducing factor)
AI129421 11q22.2^q22.3
+2 ESTs FKBP-associated protein N95144
bone marrow stromal cell antigen 1 N52293 14q32.3
tumor protein p53 (Li^Fraumeni
syndrome)
R39356 17p13.1
LIM protein R92455 4q22
human alpha 1 AF001540 11q13
+141 ESTs
Up two-fold in CTCLs Down two-fold in CTCLs
Homo sapiens mRNA for H-2K
binding factor-2a
R19314 chaperonin containing TCP1,
subunit 2 (beta)a
N38959 12
tumor rejection antigen (gp96) 1 AA598758 12q24.2^q24.3 adenylate cyclase 9a H64280 16p13.3
interleukin 2 receptor, beta AA057156 22q13.1 S-phase kinase-associated protein 2
(p45)a
R22239 5p13
human mRNA for lymphocyte
glycoprotein T1/Leu-1
AA406027 clathrin, heavy polypeptide-like 2a H54366
CD4 antigen (p55) AA451863 12pter^p12 protein phosphatase 2, regulatory
subunit BQ (PR 72)a
N63863
interleukin 15 receptor, alpha AA053285 10p15^p14 LIM proteina R92455 4q22
Homo sapiens TNF receptor-
associated factor 1 (TRAF1)
R71725 tumor necrosis factor receptor
superfamily, member 12a
R34121 1p36.2
protein phosphatase 3 W17217 8 CD36 antigen (collagen type I
receptor)
H69048 7q11.2
natural killer cell transcript 4 AA458965 16p13.3 cathepsin H AA487346 15q24^q25
tumor necrosis factor (ligand) super-
family, member 10
H54629 3q26 collagen, type XVI, alpha 1 R54778 1p35^p34
spectrin, alpha, non-erythrocytic 1
(alpha-fodrin)
T60235 9q33^q34 lymphocyte-speci¢c protein tyrosine
kinase
AA469965 1p35^p34.3
syndecan 4 (amphiglycan, ryudocan) AA148736 20q12 ¢lamin A, alpha (actin-binding
protein-280)
AA478436 Xq28
apoptosis inhibitor 1 R19628 11q22 CD47 antigen (Rh-related antigen) AA455448 3q13.1^q13.2
+4 ESTs human alpha 1 AF001540 11q13
+161 ESTs
Up two-fold in miscellaneous TCLs Down two-fold in miscellaneous TCLs
¢lamin A, alpha (actin-binding
protein-280)
AA478436 Xq28 transgelin 2a H08564 1q21^q25
natural killer cell transcript 4 AA458965 16p13.3 colony stimulating factor 3 receptor
(granulocyte)
AA443000 1p35^p34.3
S100 calcium-binding protein P R32952 4p16 myosin, light polypeptide 1, alkali ;
skeletal, fast
T52894 2q33^q34
FEBS 26219 19-6-02 Cyaan Magenta Geel Zwart
G.C. Fillmore et al./FEBS Letters 522 (2002) 183^188186
tered separately from the lymphoma cell lines, and many of
the lymphoma cell lines clustered together in groups of histo-
logically related T-cell lymphoma subtypes. For example, the
cutaneous T-lymphomas, Mac 2A and Hut 78, grouped to-
gether on one branch, while the lower-grade, clinically indo-
lent CTCL cell line HH aligned next to the other CTCLs, but
on a separate branch. The T-CLL cell line SKW-3 aligned
closely with the precursor T-ALL cell line CEM-6, and the
Jurkat (T-ALL) and SUDHL-1 cell lines also clustered in this
group. The two t(2;5) ALCLs, Karpas 299 and SUDHL-1,
did cluster next to each other; however, their branching pat-
terns were quite distinct.
3.2. Di¡erential gene expression in lymphoma cell lines
Based upon two-fold di¡erences in expression represented
by genes lying outside the blue line in Fig. 1, we identi¢ed
shared and distinct groups of up- and down-regulated genes in
each of the lymphoma cell lines relative to the CD4-positive
T-cells. Venn diagrams were used to construct lists of genes
for each of four categories of T-cell lymphoma (precursor
ALLs, t(2;5)-positive ALCLs, CTCLs, or miscellaneous
T-cell lymphomas), relative to the CD4-positive T-cells (data
not shown, see Fig. 3, Supplementary Data, http://www.
elsevier.com/PII/S0014579302029149). Greater numbers of
genes were found to be down-regulated than up-regulated in
all of the cell lines, with 1118 down-regulated genes (greater
than two-fold) and 111 up-regulated genes (greater than two-
fold) in the lymphoma cell lines as a group, relative to normal
CD4-positive T-cells. No genes were consistently up- or down-
regulated in all of the lymphoma cell lines as a group, indicat-
ing signi¢cant molecular heterogeneity in the cell lines. Even
within groups of clinicopathologically related lymphomas,
very few genes were commonly over- or under-expressed.
For example, Karpas 299 and SUDHL-1 both harbor the
chromosomal translocation t(2;5) resulting in over-expression
of the NPM-ALK oncoprotein. Surprisingly, only 15 genes
were shared in the two cell lines, three of which were over-
expressed and 12 of which were under-expressed compared to
the composite sample. The HH and Hut 78 cell lines shared
the largest number of commonly expressed genes with 135
genes that were under-expressed in both cell lines. Table 2
lists genes that were di¡erentially expressed greater than
two-fold in the four groups of cell lines. Many genes involved
in cell cycle regulation, intracellular signaling, cytoskeletal
regulation, cellular metabolism, and apoptosis were identi¢ed
as commonly deregulated genes. Many ESTs were also found
to be di¡erentially expressed.
3.3. Con¢rmation of di¡erential gene expression by quantitative
£uorescent RT-PCR
In order to con¢rm the di¡erential expression of genes re-
vealed by microarray analysis of the cell lines derived from
T-cell malignancies, we analyzed several genes by real-time
quantitative £uorescent RT-PCR. We selected several genes
di¡erentially expressed in the di¡erent cell types for our quan-
titative RT-PCR analyses. Overall, there was approximately
70% agreement between the microarray results and the quan-
titative RT-PCR data for the six genes we examined (data
not shown, see Table 3, Supplementary Data, http://www.
elsevier.com/PII/S0014579302029149).
4. Discussion
The molecular aberrations underlying many subtypes of
T-cell malignancies are largely unknown. In the current study,
we examined the gene expression pro¢les of several diverse
T-cell malignancies and compared them to those of PB
T-cells. In this report, we have shown (using hierarchical clus-
tering analysis, which groups samples based upon the similar-
ity of gene expression pro¢les) that CD4þ T-cells could be
distinguished from T-cell malignancies. The clustering analysis
revealed signi¢cant heterogeneity in most malignant T-cell
lines, and the clustering patterns were consistent with our
expectations for the di¡erent types of cell lines. Some of the
clustering patterns, however, produced interesting and surpris-
ing patterns of relatedness between the malignant categories.
For example, the two precursor T-ALLs, CEM-6 and Jurkat,
along with the SKW-3 (T-CLL) cell line and SUDHL-1, all
came o¡ one major branch, with CEM-6 and SKW-3 forming
the tightest cluster. Very little is known regarding the molec-
ular pathogenesis of T-CLLs. Although they have been
thought to represent the T-cell counterpart of B-chronic lym-
phocytic leukemia, T-CLLs are considered to be much more
clinically aggressive [34]. In this regard, the clustering of the
SKW-3 cell line with high-grade ALLs may re£ect its high
proliferative index and biological aggressiveness. Hut 78 is
an aggressive transformed counterpart of mycosis fungoides,
a low-grade CTCL, whereas Mac 2A represents lymph node
metastasis of a CD30þ cutaneous lymphoma. The close clus-
tering of Hut 78 and Mac 2A, which are both aggressive
lymphomas that transformed from two clinicopathologically
distinct cutaneous lymphomas [35], is also of interest. The two
t(2;5) ALCLs, Karpas 299 and SUDHL-1, also clustered next
to each other; however, their branching patterns were quite
distinct, with SUDHL-1 grouping with other aggressive neo-
Table 2 (Continued).
Description GenBank Map Description GenBank Map
lymphocyte-speci¢c protein 1 T83159 11p15.5 caspase 8, apoptosis-related cysteine
protease
AA448468 2q33^q34
interleukin 2 receptor, beta AA057156 22q13.1 protein tyrosine phosphatase type
IVA, member 2
AA504327 1p35
protease inhibitor 2 (anti-elastase),
monocyte/neutrophil
R54664 6p25 human alpha 1 AF001540 11q13
interferon gamma receptor 2 AA448929 21q22.1 KIAA0182 protein H05563
+1 EST adenylate cyclase 9 H64280 16p13.3
+282 ESTs
ALCL=anaplastic large cell lymphoma; ALL=acute lymphocytic leukemia; CTCL= cutaneous T-cell lymphoma; TCL=T-cell lymphoma;
EST=expressed sequence tag.
aBoth members of each class.
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plasms (Jurkat, SKW-3, and CEM-6) and Karpas 299 in its
own distinct group. Despite the common expression of the
NPM-ALK oncogene in these two cell lines, their gene ex-
pression pro¢les indicate signi¢cant molecular di¡erences
[36,37].
Comparison of gene expression to PB CD4þ T-cells dem-
onstrated numerous di¡erentially expressed genes involved in
proliferation, signaling pathways, apoptosis, and cytoskeletal
regulation in each lymphoma cell line. There was no single
gene that was di¡erentially expressed in all of the lymphoma
cell lines compared to the PB T-cells. This highlights the pres-
ence of signi¢cant molecular heterogeneity within the groups
of lymphomas. It is possible that the level of di¡erential ex-
pression of many commonly altered genes is lower than the
plus or minus two-fold change that was used as a cuto¡ point.
As many signi¢cant changes in gene expression occur via min-
ute changes in the level of mRNA transcripts, these ¢ndings
are not too surprising.
Relative to CD4þ T-cells, very few genes were similarly
expressed in the related groups of tumors. These observations
suggest that there is signi¢cant molecular heterogeneity even
within a group of clinicopathologically related entities. Recent
studies have demonstrated the existence of molecular sub-
groups within other lymphomas, such as di¡use large B-cell
lymphomas, using microarray technology [11].
Our RT-PCR validation of six genes revealed an overall
concordance rate of approximately 70%. This is in keeping
with those that have been reported in the literature [38].
The multiple, complex steps involved in cDNA preparation,
labeling, hybridization, and image analysis may be possible
reasons for the lack of perfect concordance.
Our current study demonstrates the utility of cDNA micro-
array analysis and quantitative real-time RT-PCR for the as-
sessment of transcriptional expression patterns of T-cell ma-
lignancies. Very few reports have studied the expression
pro¢le of speci¢c T-cell malignancies [39,40]. Our study rep-
resents a comprehensive global expression analysis of a di-
verse group of T-cell leukemic lymphomas with actual com-
parison to a normal T-cell population. Comparison of
expression pro¢les of T-cell malignancies to those of non-neo-
plastic CD4þ T-cells allowed the identi¢cation of a number of
genes and unknown ESTs that may potentially contribute to
the development of these neoplasms.
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